Created at	Source	Raw Value	Validated value
May 12, 2021, 12:31 a.m.	usa	Cohort A (Ambulatory) - Proportion swab negative at day 7 (Primary efficacy endpoint);Cohort A (Ambulatory) - Treatment-emergent and treatment related serious adverse events (Primary Safety Endpoint);Cohort B (Hospitalized) - Ordinal Scale (Primary Efficacy Endpoint);Cohort B (Hospitalized) - treatment-emergent and treatment-related serious adverse events (Primary Safety Endpoint)	Cohort A (Ambulatory) - Proportion swab negative at day 7 (Primary efficacy endpoint);Cohort A (Ambulatory) - Treatment-emergent and treatment related serious adverse events (Primary Safety Endpoint);Cohort B (Hospitalized) - Ordinal Scale (Primary Efficacy Endpoint);Cohort B (Hospitalized) - treatment-emergent and treatment-related serious adverse events (Primary Safety Endpoint)
Oct. 26, 2020, 11:31 p.m.	usa	Cohort B (Hospitalized) - treatment-emergent and treatment-related serious adverse events (Primary Safety Endpoint);Cohort A (Ambulatory) - Proportion swab negative at day 7 (Primary efficacy endpoint);Cohort B (Hospitalized) - Time to viral negativity (Primary Efficacy Endpoint);Cohort A (Ambulatory) - Treatment-emergent and treatment related serious adverse events (Primary Safety Endpoint)	Cohort B (Hospitalized) - treatment-emergent and treatment-related serious adverse events (Primary Safety Endpoint);Cohort A (Ambulatory) - Proportion swab negative at day 7 (Primary efficacy endpoint);Cohort B (Hospitalized) - Time to viral negativity (Primary Efficacy Endpoint);Cohort A (Ambulatory) - Treatment-emergent and treatment related serious adverse events (Primary Safety Endpoint)